[at CNBC] - Nektar fell 24 percent today after it announced its critical trial of a drug for chronic pain missed its primary endpoint. Mad Money viewers ask Jim Cramer their investment questions via Twitter.
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment